To include your compound in the COVID-19 Resource Center, submit it here.

Team identifies HIF2A as liver disease target

A paper published in Nature Medicine by researchers at the National Cancer Institute and colleagues identified intestinal endothelial PAS domain protein 1 (HIF2A; HIF-2alpha; EPAS1) as a promising target to treat hepatic steatosis. The findings suggest a new indication for small molecule

Read the full 421 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers